Zealand Pharma A/S (ZEAL)

10.09 -0.16 (-1.56%) At close: 01:03PM EDT

Zealand Pharma A/S

Sydmarken 11
Søborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 355

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Adam Sinding Steensberg M.D.	Pres & CEO	717.8k	N/A	1974
Mr. Matthew Donald Dallas	Sr. VP & CFO	578.17k	N/A	1975
Mr. Ivan Mourits Moller	Exec. VP of Technical Devel. & Operations	N/A	N/A	1972
Lani Pollworth Morvan	Investor Relations & Communications Officer	N/A	N/A	N/A
Mr. Mads Kronborg	Head of Investor Relations & Communication	N/A	N/A	N/A
Ms. Christina Sonnenborg Bredal	VP of People & Organization	N/A	N/A	1985
Ms. Hanne Heidenheim Bak	Sr. Project Director, R&D Operations Mang. and Employee Representative Director	N/A	N/A	1953
Dr. Jens Damsgaard Mikkelsen M.D.	Head of Molecular Pharmacology	N/A	N/A	N/A
Dr. Danilo Verge	Head of Global Medical Affairs	N/A	N/A	N/A
Dr. David M. Kendall M.D.	Sr. Global Medical Advisor of Metabolism	N/A	N/A	1963

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Corporate governance

Zealand Pharma A/S’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 6; Board: 1; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.